Neuro Immunoassay Market Report 2026

The neuro immunoassay (NIA) market size has grown strongly in recent years. It will grow from $2.88 billion in 2025 to $3.12 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to growing demand for sensitive neurological diagnostics, increasing adoption of immunoassay techniques in neuroscience research, rising prevalence of neurodegenerative disorders, expansion of clinical and research laboratories, and growing focus on early disease detection and monitoring.

The neuro immunoassay (NIA) market size is expected to see strong growth in the next few years. It will grow to $4.28 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing integration of neuro immunoassay (NIA) with artificial intelligence (AI) data analysis, rising investment in biomarker discovery, growing adoption of personalized medicine and therapeutic monitoring, expansion of high-throughput screening platforms, and a rise in demand for automated and precise immunoassay systems. Major trends in the forecast period include technology-driven innovations in assay sensitivity and specificity, advancements in artificial intelligence (AI)-enabled data interpretation, developments in multiplexed and lab-on-a-chip immunoassay systems, rising research and development in neuro biomarker identification, and innovation in integrated and automated neurodiagnostic platforms.

The rising prevalence of neurological disorders is expected to drive the growth of the neuro immunoassay market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, impairing normal nervous system function and causing deficits in movement, cognition, sensation, behavior, or overall bodily control. This increasing prevalence is linked to unhealthy lifestyle habits, such as poor diet, physical inactivity, smoking, excessive alcohol consumption, and chronic stress. Neuro immunoassays assist in detecting specific biomarkers in the nervous system, enabling early diagnosis and targeted treatment for patients with neurological conditions. For example, in April 2024, the National Institutes of Health (NIH), a US-based government agency, reported that approximately 6.9 million Americans aged 65 and older are living with Alzheimer’s dementia, a number projected to nearly double to 13.8 million by 2060. Consequently, the growing prevalence of neurological disorders is propelling the neuro immunoassay market.

Key companies in the neuro immunoassay market are concentrating on developing advanced solutions, such as blood-based neurological biomarker assays, to improve disease monitoring, enhance prognostic accuracy, and support clinical decision-making in neurological disorders. Blood-based neurological biomarker assays are tests that measure specific proteins, such as Neurofilament Light Chain (NfL), in human serum or plasma to evaluate neuronal injury and disease activity. For example, in June 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, received CE marking for its Neurofilament Light Chain blood test, designed for use on the Atellica IM Analyzer and ADVIA Centaur systems. The test quantifies NfL levels to help predict neuronal injury risk in adults with relapsing multiple sclerosis, complementing clinical, imaging, and laboratory assessments. The CE mark indicates compliance with European In Vitro Diagnostic Regulations, broadening access to standardized neuro immunoassay diagnostics across European laboratories.

In May 2025, Sanofi, a France-based biopharmaceutical company specializing in immunology, vaccines, and neuroscience research, acquired Vigil Neuroscience Inc. for approximately $470 million. This acquisition allows Sanofi to strengthen its early-stage neurology and neuroimmunology research by incorporating Vigil’s oral TREM2 agonist VG 3927, a candidate targeting microglial immune pathways relevant to Alzheimer’s disease, into its development pipeline. Vigil Neuroscience Inc. is a US-based clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer’s disease, with programs centered on immune-modulating mechanisms in the central nervous system.

Major companies operating in the neuro immunoassay market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Abcam plc, BioLegend Inc., Meso Scale Diagnostics LLC, Sino Biological Inc., Quanterix Corporation, Cusabio Technology LLC, OriGene Technologies Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Assay Genie Ltd., Novus Biologicals LLC, Creative Diagnostics, MyBioSource Inc., Immuno-Biological Laboratories Co. Ltd., Boster Biological Technology, Cloud-Clone Corp., FineTest Biotech Inc., Abbexa Ltd.

North America was the largest region in the neuro immunoassay (NIA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuro immunoassay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuro immunoassay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the neuro immunoassay market by increasing costs of imported reagents, assay kits, laboratory instruments, and analytical equipment used in biomarker detection and diagnostics. north america and europe are most affected due to dependence on specialized biochemical imports, while asia-pacific faces cost pressure on manufacturing and export of diagnostic kits. these tariffs are increasing testing costs and slowing laboratory procurement cycles. at the same time, they are encouraging local reagent production, regional manufacturing of analyzers, and strengthened domestic diagnostic supply chains.

Neuro immunoassay refers to immunoassay techniques specifically developed to detect and measure biomarkers and analytes associated with neurological disorders and brain function. Its main purpose is to facilitate accurate diagnosis, monitoring, and research of neurological conditions through highly sensitive and specific biochemical assays. It also aids in drug development, personalized medicine, and the study of neurodegenerative and neuroinflammatory diseases.

The key product types of neuro-immunoassay include reagents and kits, and analyzers. Reagents and kits detect neurological biomarkers in biological samples for diagnosis and research. Technologies include radioimmunoassay, PCR, ELISA, western blot, rapid tests, and ELISPOT. Biomarkers include amyloid-beta, tau, alpha-synuclein, NFL, autoantibodies, cytokines, GFAP, NSE, UCH-L1, and BDNF. Applications include Alzheimer’s, Parkinson’s, Huntington’s, ALS, and SMA, across hospitals, clinics, academia, and pharma.

The neuro immunoassay market consists of revenues earned by entities by providing services such as enzyme-linked immunosorbent assay (ELISA) kits, multiplex immunoassay platforms, chemiluminescent immunoassays, electrochemiluminescent immunoassays, and high-throughput assay systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuro immunoassay (NIA) includes sales of assay reagents, detection instruments, sample preparation kits, and automated immunoassay analyzers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.